Printer Friendly

Intellipharmaceutics announces Teva's launch of 5mg Focalin XR generic.

NORDIC BUSINESS REPORT-November 21, 2014-Intellipharmaceutics announces Teva's launch of 5mg Focalin XR generic


Pharmaceutical company Intellipharmaceutics International (TSX:I) said on Thursday that Teva Pharmaceuticals has launched the generic version of the 5mg strength of its dexmethylphenidate hydrochloride generic of Focalin XR(R).

Intellipharmaceutics said that on 18 November 2013, it received a conditional approval from the US Food and Drug Administration (FDA) to launch its own generic version of 5mg Focalin XR upon the expiry of six months from the date of marketplace launch in the US by Teva, which is the first to file for approval of the 5mg strength.

In addition, Intellipharmaceutics' manufacturing, marketing and distribution partner for Focalin XR generics in the US, Par Pharmaceutical, intends to launch this 5mg strength strength immediately upon the expiry of the exclusivity period six months after the date of launch of the 5mg strength by Teva.

((Comments on this story may be sent to

COPYRIGHT 2014 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2014 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Nordic Business Report
Date:Nov 21, 2014
Previous Article:CTT Systems AB receives order for its Cair system from AERIA Luxury Interiors.
Next Article:Opus Group's profit up to SEK111.1m in January to September 2014 period.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters